European Commission outlines proposed role of Committee for Advanced Therapies - CAT
This article was originally published in Clinica
Executive Summary
The European Commission has now outlined the structure and responsibilities of the new Committee for Advanced Therapies (CAT), whose responsibilities will include advising on the quality, safety and efficacy of human tissue engineered products (hTEPs). The role of the committee, which will be part of the European Medicines Evaluation Agency (EMEA), is spelt out within the Commission's just published proposal for a Regulation on advanced tissue products.